Scarica l'app Stockscreener
12.48
1.03%
-0.13
Precedente Chiudi:
$12.61
Aprire:
$12.73
Volume 24 ore:
190.26K
Relative Volume:
0.59
Capitalizzazione di mercato:
$213.48M
Reddito:
$10.73M
Utile/perdita netta:
$-455.74M
Rapporto P/E:
-5.2547
EPS:
-2.375
Flusso di cassa netto:
$-502.70M
1 W Prestazione:
+6.94%
1M Prestazione:
-5.67%
6M Prestazione:
-82.64%
1 anno Prestazione:
-57.49%
Intervallo 1D:
$12.28
$12.82
Intervallo di 1 settimana:
$11.40
$12.82
Portata 52W:
$11.40
$73.06
Atrium Therapeutics Inc Stock (RNA) Company Profile
Nome
Atrium Therapeutics Inc
Settore
Industria
Telefono
858-401-7900
Indirizzo
3020 CALLAN ROAD, SAN DIEGO, CA
Compare RNA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNA
Atrium Therapeutics Inc
|
12.48 | 218.10M | 10.73M | -455.74M | -502.70M | -2.375 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atrium Therapeutics Inc Stock (RNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Iniziato | Wells Fargo | Overweight |
| 2025-09-17 | Iniziato | Roth Capital | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-06-24 | Iniziato | Bernstein | Outperform |
| 2025-06-17 | Iniziato | Wolfe Research | Outperform |
| 2025-06-11 | Iniziato | Raymond James | Strong Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-09-24 | Iniziato | Goldman | Buy |
| 2024-08-28 | Iniziato | Barclays | Overweight |
| 2024-05-03 | Iniziato | BofA Securities | Buy |
| 2024-03-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
| 2022-07-12 | Iniziato | Raymond James | Strong Buy |
| 2021-09-07 | Iniziato | Evercore ISI | Outperform |
| 2021-06-17 | Iniziato | Needham | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | Cowen | Outperform |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | SVB Leerink | Outperform |
| 2020-07-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Atrium Therapeutics Inc Borsa (RNA) Ultime notizie
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Unveiling a 111.86% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower Loss Beats Estimates Amid Pipeline Progress - newsline.com
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: EPS Beats Estimates Despite Pre-Revenue Status; Stock Drops on Cash Burn ConcernsEPS Miss Report - newsline.com
Atrium Therapeutics (RNA) Slips 2.28% as Biotech Sector Faces HeadwindsPCR Moving Average - newsline.com
Atrium Therapeutics, Inc. (RNA) - DirectorsTalk Interviews
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Operational DisciplineBuyback Announcement Report - newsline.com
RNA Price Today: Atrium Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Here's Why We're Not Too Worried About Atrium Therapeutics' (NASDAQ:RNA) Cash Burn Situation - Yahoo Finance
Atrium Therapeutics Inc. (RNA) Holds Steady Near Resistance as Momentum BuildsCash Flow Strong Stocks - newsline.com
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring a 90.99% Potential Upside in RNA Therapeutics - DirectorsTalk Interviews
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Investor Sentiment - Newser
Atrium Therapeutics (RNA) Stages a Recovery: Testing Key Resistance at $13.69Crowd Stock Picks - Newser
Atrium Therapeutics Inc - Reuters
RNA Initiated Coverage by Leerink Partners -- Rating Set to Outp - GuruFocus
RA Capital (RNA) healthcare fund discloses 864,102 shares, 5.6% stake - Stock Titan
Leerink initiates Atrium Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
Leerink Partners Initiates Atrium Therapeutics(RNA.US) With Buy Rating, Announces Target Price $25 - Moomoo
Leerink Partners Initiates Coverage on Atrium Therapeutics With Outperform Rating, $25 PT - Moomoo
Atrium Therapeutics 1Q Loss/Shr 97c >RNA - Moomoo
Atrium Therapeutics Reports First Quarter 2026 Financial Results - Investing News Network
Atrium Therapeutics 1Q Rev $19.6M >RNA - Moomoo
Atrium Therapeutics Believes Cash Resources Sufficient to Fund Planned Ops Through Key Clinical Proof-Of-Concept Milestones >RNA - Moomoo
Atrium Therapeutics (RNA) Q1 2026: milestone revenue, higher R&D and $267.8M cash - Stock Titan
Atrium Therapeutics Reports Q1 2026 Financial Results and Corporate Progress - Intellectia AI
Atrium Therapeutics reports Q1 2026: $19.6M collaboration revenue, $267.8M cash - TradingView
Atrium Therapeutics, Inc. 1Q 2026: Revenue $19.6M, EPS $(0.97) — 10-Q Summary - TradingView
Atrium Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Atrium Therapeutics Q1 collaboration revenue surges after spin-off - TradingView
Atrium Therapeutics (Nasdaq: RNA) Q1 2026 results show higher revenue and loss - Stock Titan
Fierce Biotech Fundraising Tracker '26: Create corrals $122M; Isomorphic's $2B series B - Fierce Biotech
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring the 91% Potential Upside in RNA Therapeutics - DirectorsTalk Interviews
RNA (Atrium Therapeutics) revenue surges 70.8% in Q1, but shares slip as losses persist.Investment Community Signals - newser.com
How Atrium Therapeutics (RNA) performance compares to expectations (Underperforming) 2026-05-08Earnings Miss Risk - Newser
What Atrium Therapeutics (RNA) is doing to earn customer loyalty (Nudges Up) 2026-05-06Index Investing - newser.com
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring an 86% Potential Upside in RNA Therapeutics - DirectorsTalk Interviews
RNA 260618 33.00P (RNA260618P33000) Stock Options Chain | Quotes & News - Moomoo
Atrium Therapeutics (RNA) price target decreased by 65.57% to 25.50 - MSN
BlackRock (NASDAQ: RNA) reports 5.2% stake — 892,387 shares - Stock Titan
Milestone in Atrium and BMS cardiovascular collaboration - BioWorld News
BMY Secures $15M Milestone Payment to Atrium Therapeutics - GuruFocus
Atrium Therapeutics earns $15M from Bristol Myers Squibb By Investing.com - Investing.com South Africa
Atrium Therapeutics earns $15M from Bristol Myers Squibb - Investing.com
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration - PR Newswire
RNA SEC FilingsAtrium Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RNA (Atrium Therapeutics Inc.) posts 70.8 percent year over year Q1 2026 revenue growth, shares rise 3.71 percent. - Xã Thanh Hà
Atrium Therapeutics Inc Azioni (RNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Atrium Therapeutics Inc Azioni (RNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Boyce Sarah | President and CEO |
Jan 21 '26 |
Sale |
72.45 |
14,387 |
1,042,338 |
269,007 |
| Flanagan W. Michael | Chief Scientific Officer |
Jan 21 '26 |
Sale |
72.45 |
6,534 |
473,388 |
85,093 |
| MacLean Michael F | Chief Financial Officer |
Jan 21 '26 |
Sale |
72.45 |
4,542 |
329,068 |
59,290 |
| LEVIN ARTHUR A | Director |
Jan 21 '26 |
Sale |
72.45 |
1,758 |
127,367 |
16,562 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 21 '26 |
Sale |
72.45 |
2,929 |
212,206 |
113,938 |
| Boyce Sarah | President and CEO |
Jan 07 '26 |
Sale |
72.23 |
8,576 |
619,444 |
283,394 |
| Calderaro Charles III | Chief Technical Officer |
Jan 07 '26 |
Sale |
72.23 |
3,727 |
269,201 |
49,797 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 07 '26 |
Sale |
72.23 |
1,965 |
141,932 |
116,867 |
| Moriarty John B | Chief Legal Officer |
Jan 07 '26 |
Sale |
72.23 |
2,374 |
171,474 |
74,557 |
| MacLean Michael F | Chief Financial Officer |
Jan 07 '26 |
Sale |
72.23 |
1,974 |
142,582 |
63,832 |
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):